Anti-tumor activity of metformin: from metabolic and epigenetic perspectives.
Anti-tumor activity of metformin: from metabolic and epigenetic perspectives.
复制标题
二甲双胍的抗肿瘤活性：从代谢和表观遗传学的角度
DOI：
10.18632/oncotarget.13639
复制
发表时间：
2017-01-17
期刊：
影响因子：
--
通讯作者：
Li S
中科院分区：
文献类型：
--
作者：
Yu X;Mao W;Zhai Y;Tong C;Liu M;Ma L;Yu X;Li S
二甲双胍用于治疗2型糖尿病已有50多年的历史。流行病学、临床前和临床研究表明，二甲双胍治疗可降低糖尿病患者的癌症发病率。由于二甲双胍作为一种潜在的抗癌药物，其成本低廉，引起了人们的强烈研究兴趣。其传统的抗癌机制包括间接和直接的胰岛素依赖途径。本文从细胞代谢和表观遗传修饰两个方面探讨了二甲双胍的抗肿瘤作用机制。本文还介绍了二甲双胍在抗癌免疫和细胞凋亡中的作用。了解这些机制将有助于二甲双胍在临床试验和抗癌治疗开发中的应用。
Metformin has been used to treat type 2 diabetes for over 50 years. Epidemiological, preclinical and clinical studies suggest that metformin treatment reduces cancer incidence in diabetes patients. Due to its potential as an anti-cancer agent and its low cost, metformin has gained intense research interest. Its traditional anti-cancer mechanisms involve both indirect and direct insulin-dependent pathways. Here, we discussed the anti-tumor mechanism of metformin from the aspects of cell metabolism and epigenetic modifications. The effects of metformin on anti-cancer immunity and apoptosis were also described. Understanding these mechanisms will shed lights on application of metformin in clinical trials and development of anti-cancer therapy.